231 related articles for article (PubMed ID: 36809678)
1. Real-world impact of once-weekly subcutaneous semaglutide after 2 years of follow-up: Results from a nationwide observational study in people with type 2 diabetes.
Vilsbøll T; Lindahl CØ; Nielsen NF; Tikkanen CK
Diabetes Obes Metab; 2023 Jun; 25(6):1740-1749. PubMed ID: 36809678
[TBL] [Abstract][Full Text] [Related]
2. Once-weekly subcutaneous semaglutide treatment for persons with type 2 diabetes: Real-world data from a diabetes out-patient clinic.
Hansen KB; Svendstrup M; Lund A; Knop FK; Vilsbøll T; Vestergaard H
Diabet Med; 2021 Oct; 38(10):e14655. PubMed ID: 34291491
[TBL] [Abstract][Full Text] [Related]
3. Real-World Effectiveness of Once-Weekly Semaglutide From a US Commercially Insured and Medicare Advantage Population.
Visaria J; Uzoigwe C; Swift C; Dang-Tan T; Paprocki Y; Willey VJ
Clin Ther; 2021 May; 43(5):808-821. PubMed ID: 33785221
[TBL] [Abstract][Full Text] [Related]
4. Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).
Tan X; Divino V; Amamoo J; Xie L; Coyle KB; Gamble CL; Guevarra M; Paprocki Y; King AA
Clin Drug Investig; 2024 Apr; 44(4):271-284. PubMed ID: 38507188
[TBL] [Abstract][Full Text] [Related]
5. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups.
Yale JF; Bodholdt U; Catarig AM; Catrina S; Clark A; Ekberg NR; Erhan U; Holmes P; Knudsen ST; Liutkus J; Sathyapalan T; Schultes B; Rudofsky G
BMJ Open Diabetes Res Care; 2022 Apr; 10(2):. PubMed ID: 35383100
[TBL] [Abstract][Full Text] [Related]
6. Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain.
Garcia de Lucas MD; Miramontes-González JP; Avilés-Bueno B; Jiménez-Millán AI; Rivas-Ruiz F; Pérez-Belmonte LM
Front Endocrinol (Lausanne); 2022; 13():995646. PubMed ID: 36187123
[TBL] [Abstract][Full Text] [Related]
7. Semaglutide once weekly in people with type 2 diabetes: Real-world analysis of the Canadian LMC diabetes registry (SPARE study).
Brown RE; Bech PG; Aronson R
Diabetes Obes Metab; 2020 Nov; 22(11):2013-2020. PubMed ID: 32538541
[TBL] [Abstract][Full Text] [Related]
8. Once-Weekly Semaglutide Use in Type 2 Diabetes: Real-World Data from the SURE Netherlands Observational Study.
Wolffenbuttel BHR; Brugts MP; Catarig AM; Clark A; Kok M; Lieverse AG; van Soest J
Adv Ther; 2023 Mar; 40(3):920-933. PubMed ID: 36542260
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
[TBL] [Abstract][Full Text] [Related]
10. Use of once-weekly semaglutide in patients with type 2 diabetes in routine clinical practice: Results from the SURE Canada multicentre, prospective, observational study.
Yale JF; Catarig AM; Grau K; Harris S; Klimek-Abercrombie A; Rabasa-Lhoret R; Reardon L; Woo V; Liutkus J
Diabetes Obes Metab; 2021 Oct; 23(10):2269-2278. PubMed ID: 34142429
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation.
Meier JJ
Front Endocrinol (Lausanne); 2021; 12():645617. PubMed ID: 34248838
[TBL] [Abstract][Full Text] [Related]
12. Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis.
Hansen BB; Nuhoho S; Ali SN; Dang-Tan T; Valentine WJ; Malkin SJP; Hunt B
J Med Econ; 2020 Jun; 23(6):650-658. PubMed ID: 31990244
[No Abstract] [Full Text] [Related]
13. Comparing once-weekly semaglutide to incretin-based therapies in patients with type 2 diabetes: a systematic review and meta-analysis.
Mishriky BM; Cummings DM; Powell JR; Sewell KA; Tanenberg RJ
Diabetes Metab; 2019 Apr; 45(2):102-109. PubMed ID: 30243806
[TBL] [Abstract][Full Text] [Related]
14. Dose-response effects on HbA
Blüher M; Rosenstock J; Hoefler J; Manuel R; Hennige AM
Diabetologia; 2024 Mar; 67(3):470-482. PubMed ID: 38095657
[TBL] [Abstract][Full Text] [Related]
15. Injectable semaglutide and reductions in HbA1c and weight in the real world in people switched from alternative glucagon-like peptide-1 receptor agonists.
Crabtree TSJ; Adamson K; Reid H; Barnes D; Sivappriyan S; Bickerton A; Gallen IW; Field BCT; Idris I; Ryder REJ;
Diabetes Obes Metab; 2022 Jul; 24(7):1398-1401. PubMed ID: 35322528
[TBL] [Abstract][Full Text] [Related]
16. Once-weekly semaglutide use in patients with type 2 diabetes: Real-world data from the SURE Italy observational study.
Napoli R; Berra C; Catarig AM; Di Loreto C; Donatiello E; Berentzen TL; Pitocco D; Giorgino F
Diabetes Obes Metab; 2023 Jun; 25(6):1658-1667. PubMed ID: 36789682
[TBL] [Abstract][Full Text] [Related]
17. Impact on HbA1c and body weight of switching from other GLP-1 receptor agonists to semaglutide: A model-based approach.
Overgaard RV; Lindberg SØ; Thielke D
Diabetes Obes Metab; 2019 Jan; 21(1):43-51. PubMed ID: 30047216
[TBL] [Abstract][Full Text] [Related]
18. Once-weekly semaglutide use in glucagon-like peptide-1 receptor agonist naïve patients with type 2 diabetes in North Macedonia: Real-world data from the MIRAGE study.
Milenkovikj T; Chekorova Mitreva B; Jovanovska Mishevska S; Bitoska-Mileva I; Ahmeti I;
Diabetes Res Clin Pract; 2023 Dec; 206():111018. PubMed ID: 37972857
[TBL] [Abstract][Full Text] [Related]
19. Effect of tirzepatide on glycaemic control and weight loss compared with other glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes mellitus.
Tsukamoto S; Tanaka S; Yamada T; Uneda K; Azushima K; Kinguchi S; Wakui H; Tamura K
Diabetes Obes Metab; 2024 Jan; 26(1):262-274. PubMed ID: 37828829
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and Tolerability of Once-Weekly GLP-1 Receptor Agonists in Clinical Practice: A Focus on Switching Between Once-Weekly Molecules in Type 2 Diabetes.
Di Dalmazi G; Coluzzi S; Baldassarre MPA; Ghit A; Graziano G; Rossi MC; Ciappini B; Milo M; Carrieri F; Nicolucci A; Consoli A; Formoso G
Front Endocrinol (Lausanne); 2022; 13():892702. PubMed ID: 35909534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
